Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted — Trials · CancerIndex

Clinical trials

Registered studies

3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA)	recruiting	Phase 3	365	Nuvation Bio Inc.INDUSTRY	3	Aug 28, 2026	clinicaltrials

Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials